Cranbury, N.J.-based Amicus Therapeutics and the Perelman School of Medicine at the University of Pennsylvania are expanding their gene therapy collaboration.

Newron must delay a trial of the Swiss-listed drugmaker’s prospective schizophrenia medicine evenamide after the U.S. FDA raised concerns about CNS events that emerged in rats and dogs.

Novartis’ gene therapy treatment for spinal muscular atrophy could receive marketing approval as early as May 2019 after the U.S. Food and Drug Administration granted AVXS-101, now dubbed Zolgensma, priority review.